# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-26-006269
**Filing Date:** 2026-6
**Character Count:** 7197
**Document Hash:** 98309879005e7e412f28285baa60e7e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-006269.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001654954-26-006269

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260629

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 261132292

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

 **UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2026

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

TR-1: Standard form for notification of major holdings

 **1. Issuer Details**

 **ISIN** 

GB00BN7SWP63<br>

 **Issuer Name**

GSK PLC<br>

 **UK or Non-UK Issuer**

UK<br>

 **2. Reason for Notification**

An acquisition or disposal of voting rights<br>

 **3. Details of person subject to the notification obligation**

 **Name**

Dodge & Cox<br>

 **City of registered office (if applicable)**

San Francisco<br>

 **Country of registered office (if applicable)**

USA<br>

 **4. Details of the shareholder**

 **Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above**

 **City of registered office (if applicable)**

 **Country of registered office (if applicable)**

 **5. Date on which the threshold was crossed or reached**

24-Jun-2026<br>

 **6. Date on which Issuer notified**

26-Jun-2026<br>

 **7. Total positions of person(s) subject to the notification obligation**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **% of voting rights attached to shares (total of 8.A)**<br>| **% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)**<br>| **Total of both in % (8.A + 8.B)**<br>| **Total number of voting rights held in issuer**<br>|
| Resulting situation on the date on which threshold was crossed or reached<br>| 4.960000<br>| 0.000000<br>| 4.960000<br>| 201065668<br>|
| Position of previous notification (if applicable)<br>| 5.010000<br>| 0.000000<br>| 5.010000<br>|  |

---

 **8. Notified details of the resulting situation on the date on which the threshold was crossed or reached**

 **8A. Voting rights attached to shares**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Class/Type of shares ISIN code(if possible)**<br>| **Number of direct voting rights (DTR5.1)**<br>| **Number of indirect voting rights (DTR5.2.1)**<br>| **% of direct voting rights (DTR5.1)**<br>| **% of indirect voting rights (DTR5.2.1)**<br>|
| Ordinary GB00BN7SWP63<br>|  | 88816040<br>|  | 2.190000<br>|
| ADRs US37733W2044<br>|  | 112249628<br>|  | 2.770000<br>|
| Sub Total 8.A<br>| 201065668 | 201065668 | 4.960000% | 4.960000% |

---

 **8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Type of financial instrument**<br>| **Expiration date**<br>| **Exercise/conversion period**<br>| **Number of voting rights that may be acquired if the instrument is exercised/converted**<br>| **% of voting rights**<br>|
| Sub Total 8.B1<br>|  |  |  |  |

---

 **8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Type of financial instrument**<br>| **Expiration date**<br>| **Exercise/conversion period**<br>| **Physical or cash settlement**<br>| **Number of voting rights**<br>| **% of voting rights**<br>|
| Sub Total 8.B2<br>|  |  |  |  |  |

---

 **9. Information in relation to the person subject to the notification obligation**

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | 1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. |
| **Ultimate controlling person**<br>| **Name of controlled undertaking**<br>| **% of voting rights if it equals or is higher than the notifiable threshold**<br>| **% of voting rights through financial instruments if it equals or is higher than the notifiable threshold**<br>| **Total of both if it equals or is higher than the notifiable threshold** |

---

 **10. In case of proxy voting**

 **Name of the proxy holder**

 **The number and % of voting rights held**

 **The date until which the voting rights will be held**

 **If date does not apply, explain below**

 **11. Additional Information**

 **12. Date of Completion**

26-Jun-2026<br>

 **13. Place Of Completion**

San Francisco, California, United States of America<br>

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: June 29, 2026 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---